FDA Rejects CAPR’s Cell Therapy BLA for Genetic Disorder, Stock Tanks – July 14, 2025
Key Takeaways CAPR’s BLA for deramiocel in DMD cardiomyopathy received an FDA complete response letter. The FDA cited…
The Stock Market’s TACO Trade May Be About to Backfire
Buying the dip during recent tariff volatility has been a profitable strategy this year, but will the so-called…